In a recent webinar, Prof Lena Heiser-Garvey, an expert in anesthesiology and allergology, provided an in-depth exploration of drug allergies, particularly focusing on penicillin and non-steroidal anti-inflammatory drugs (NSAIDs).
To watch a replay of this webinar and still earn a CPD point, go to: https://event.webinarjam.com/replay/816/ gqknqaxngs4mwfz43hxk13. Email john.woodford@newmedia.co.za to let him know to allocate your point/ request an attendance certificate for those who don’t fall under the HPCSA.
Sponsored by Thermo Fisher, the session highlighted the growing prevalence of drug allergy referrals in clinical settings, with a significant number linked to antibiotics, especially penicillins.
Prof Garvey presented findings from a comprehensive five-year study involving 1 913 drug provocations. The data revealed that while specific IgE tests for penicillin could identify allergic responses, approximately 11% of patients with negative IgE tests still exhibited positive reactions during provocations. Notably, most of these reactions were delayed-type, such as rashes from amoxicillin, rather than immediate.
This finding emphasises the necessity for thorough investigations into reported drug allergies, as many patients may experience non-allergic side effects rather than true allergies.
The discussion underscored the critical importance of addressing penicillin allergies, particularly in light of the rising issue of antimicrobial resistance. In Denmark, where penicillin is a first-line treatment for various infections, accurately identifying patients with genuine allergies is essential. Prof Garvey noted that about 10% of hospital inpatients report a penicillin allergy, yet 80%-90% of these cases can be disproven through proper investigation. To effectively manage drug allergies, Prof Garvey advocated for a risk stratification approach. This method involves tailoring investigations based on the patient's reported history and the associated risk level of their symptoms. For patients at high risk of severe reactions, such as anaphylaxis, more extensive testing is warranted, including specific IgE blood tests prior to any skin testing. This approach aims to minimise the risk of provoking an allergic reaction during the diagnostic process. The presentation also addressed NSAID allergies, which vary geographically and are often not IgE-mediated. Prof Garvey explained that while NSAIDs can cause various allergic reactions, many patients tolerate selective COX-2 inhibitors, which are frequently used in clinical practice.
A significant portion of the webinar focused on perioperative hypersensitivity, a challenging area in drug allergy investigations. Prof Garvey emphasised the need for collaboration between anesthesiologists and allergists to ensure comprehensive patient care. She shared a case study of a patient who experienced a reaction during surgery, illustrating the complexities of identifying the true allergen in a setting with multiple potential triggers. Through careful testing, the patient was found to be allergic to chlorhexidine, highlighting the importance of thorough investigation in perioperative settings.
In conclusion, Prof Garvey's presentation emphasised the critical need for accurate diagnosis and management of drug allergies, particularly in the context of rising antimicrobial resistance and the complexities of perioperative care. By employing a risk-based approach to investigations and fostering collaboration among specialists, healthcare providers can improve patient outcomes and reduce the burden of unnecessary drug allergy labels. The insights shared during the webinar are vital for clinicians navigating the intricate landscape of drug allergies in their practice, ultimately aiming to enhance patient safety and treatment efficacy.
